Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ATRA Atara Biotherapeutics

Pre-Market Trading 04-09 07:10:16 EDT

5.59

-0.14

-2.44%

盘前6.29

+0.70+12.52%

04:39 EDT

High6.22	Low5.32	Vol24.56K
Open6.08	D1 Closing5.73	Amplitude15.76%
Mkt Cap32.75M	Tradable Cap23.34M	Total Shares5.86M
T/O139.19K	T/O Rate0.59%	Tradable Shares4.17M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ATRA","market":"US","secType":"STK","nameCN":"Atara Biotherapeutics","latestPrice":5.59,"timestamp":1744142400000,"preClose":5.73,"halted":0,"volume":24560,"hourTrading":{"tag":"盘前","latestPrice":6.29,"preClose":5.59,"latestTime":"04:39 EDT","volume":2,"amount":12.6900006,"timestamp":1744187953632},"delay":0,"floatShares":4174804,"shares":5858909,"eps":-11.405315,"marketStatus":"Pre-Market Trading","change":-0.14,"latestTime":"04-09 07:10:16 EDT","open":6.08,"high":6.223,"low":5.32,"amount":139193.5544,"amplitude":0.157592,"askPrice":7.59,"askSize":300,"bidPrice":4.67,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-11.405315,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1744205400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1413432000000,"exchange":"NASDAQ","adjPreClose":5.59,"preHourTrading":{"tag":"盘前","latestPrice":6.29,"preClose":5.59,"latestTime":"04:39 EDT","volume":2,"amount":12.6900006,"timestamp":1744187953632},"postHourTrading":{"tag":"盘后","latestPrice":5.59,"preClose":5.59,"latestTime":"19:58 EDT","volume":17,"amount":98.04,"timestamp":1744156693068},"volumeRatio":0.3907866019847121,"impliedVol":0.0156,"impliedVolPercentile":0.0204},"requestUrl":"/m/hq/s/ATRA","defaultTab":"news","newsList":[{"id":"2525756320","title":"BRIEF-Atara Biotherapeutics Inc - On March 31, Entered Amendment To Commercialization Agreement With Pierre Fabre - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525756320","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525756320?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 06:05","pubTimestamp":1743804326,"startTime":"0","endTime":"0","summary":"BRIEF-Atara Biotherapeutics Inc - On March 31, Entered Amendment To Commercialization Agreement With Pierre Fabre - SEC FilingApril 4  - Atara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS INC - ON MARCH 31, ENTERED AMENDMENT TO COMMERCIALIZATION AGREEMENT WITH PIERRE FABRE - SEC FILINGATARA BIOTHERAPEUTICS INC - BIO TO RECEIVE UP TO $550 MILLION IN MILESTONE PAYMENTS - SEC FILINGATARA BIOTHERAPEUTICS INC - PIERRE FABRE TO ASSUME COSTS FOR FDA REMEDIATION TO SUPPORT BLA RESUBMISSION FOR TAB-CEL - SEC FILINGSource text: [ID:n0000950170-25-051121]Further company coverage: ATRA.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI1KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2525753054","title":"Atara Biotherapeutics Inc - Pierre Fabre to Assume Costs for FDA Remediation to Support Bla Resubmission for Tab-Cel - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525753054","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525753054?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:32","pubTimestamp":1743798731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI1KZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2525730653","title":"Atara Biotherapeutics Inc - Bio to Receive up to $550 Mln in Milestone Payments - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525730653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525730653?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:32","pubTimestamp":1743798731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI1KZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2525655730","title":"Atara Biotherapeutics Inc - on March 31, Entered Amendment to Commercialization Agreement With Pierre Fabre - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2525655730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525655730?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 04:32","pubTimestamp":1743798731,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI1KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2524063009","title":"BRIEF-Atara Biotherapeutics Inc - Eric Hyllengren To Step Down As CFO And COO Of Atara Biotherapeutics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524063009","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524063009?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 06:31","pubTimestamp":1743460289,"startTime":"0","endTime":"0","summary":"BRIEF-Atara Biotherapeutics Inc - Eric Hyllengren To Step Down As CFO And COO Of Atara Biotherapeutics - SEC FilingAtara Biotherapeutics Inc ATRA.O:ATARA BIOTHERAPEUTICS INC - ERIC HYLLENGREN TO STEP DOWN AS CFO AND COO OF ATARA BIOTHERAPEUTICS - SEC FILINGSource text: [ID:n0001193125-25-068789]Further company coverage: ATRA.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE1FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2524749972","title":"Atara Biotherapeutics Inc - Eric Hyllengren to Step Down as CFO and COO of Atara Biotherapeutics - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2524749972","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524749972?lang=en_us&edition=full_marsco","pubTime":"2025-04-01 04:31","pubTimestamp":1743453112,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nFWN3QE1FN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2518723772","title":"Atara Biotherapeutics: Strategic Focus on Ebvallo BLA Resubmission and Market Position Enhancement","url":"https://stock-news.laohu8.com/highlight/detail?id=2518723772","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518723772?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 22:45","pubTimestamp":1741704333,"startTime":"0","endTime":"0","summary":"Canaccord Genuity analyst John Newman has maintained their bullish stance on ATRA stock, giving a Buy rating on March 9. John Newman’s rating is ba...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/atara-biotherapeutics-strategic-focus-on-ebvallo-bla-resubmission-and-market-position-enhancement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/atara-biotherapeutics-strategic-focus-on-ebvallo-bla-resubmission-and-market-position-enhancement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2518776749","title":"Atara Biotherapeutics Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2518776749","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518776749?lang=en_us&edition=full_marsco","pubTime":"2025-03-11 21:18","pubTimestamp":1741699080,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ATRA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 11, 2025 09:18 ET (13:18 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA"],"gpt_icon":0},{"id":"2518923056","title":"Atara Biotherapeutics (ATRA) Receives a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2518923056","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518923056?lang=en_us&edition=full_marsco","pubTime":"2025-03-10 08:25","pubTimestamp":1741566313,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) yesterday. The company’s shares closed last ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/atara-biotherapeutics-atra-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/atara-biotherapeutics-atra-receives-a-buy-from-td-cowen?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4566","BK4127","ATRA","TD","COWN","BK4207","BK4585"],"gpt_icon":0},{"id":"2518283787","title":"Atara Biotherapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2518283787","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518283787?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 21:02","pubTimestamp":1741525360,"startTime":"0","endTime":"0","summary":"NasdaqGS:ATRA Earnings and Revenue Growth March 9th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 14%. Earnings per share  missed analyst estimates by 86%.Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's share price is broadly unchanged from a week ago.We should say that we've discovered 6 warning signs for Atara Biotherapeutics (4 shouldn't be ignored!) that you should be aware of before investing here.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atara-biotherapeutics-full-2024-earnings-130240644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATRA"],"gpt_icon":0},{"id":"2518000477","title":"Atara Biotherapeutics Faces Potential Liquidation: Strategic Decisions Crucial for Investor Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2518000477","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518000477?lang=en_us&edition=full_marsco","pubTime":"2025-03-09 14:02","pubTimestamp":1741500141,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Inc (ATRA) has disclosed a new risk, in the Corporate Activity and Growth category. Atara Biotherapeutics Inc faces significa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atara-biotherapeutics-faces-potential-liquidation-strategic-decisions-crucial-for-investor-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atara-biotherapeutics-faces-potential-liquidation-strategic-decisions-crucial-for-investor-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2517907454","title":"Atara Biotherapeutics Reports 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2517907454","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517907454?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 12:03","pubTimestamp":1741406638,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics Inc ( ($ATRA) ) has released its Q4 earnings. Here is a breakdown of the information Atara Biotherapeutics Inc presented to i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/atara-biotherapeutics-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/atara-biotherapeutics-reports-2024-financial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ATRA"],"gpt_icon":0},{"id":"2517467101","title":"Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2517467101","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517467101?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 06:10","pubTimestamp":1741385401,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics  came out with a quarterly loss of $1.19 per share versus the Zacks Consensus Estimate of a loss of $3.82. This compares to loss of $14 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 68.85%. A quarter ago, it was expected that this drug developer would post a loss of $3.77 per share when it actually produced a loss of $2.93, delivering a surprise of 22.28%.Atara Biotherapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $32.75 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 150.02%. This compares to year-ago revenues of $4.25 million. The company has topped consensus revenue estimates three times over the last four quarters.Atara Biotherapeutics shares have lost about 48.9% since the beginning of the year versus the S&P 500's decline of -2.4%.While Atara Biotherapeutics has underperformed the ma","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atara-biotherapeutics-atra-reports-q4-221001602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATRA"],"gpt_icon":0},{"id":"2517546695","title":"Atara Biotherapeutics to Cut Half of Workforce Amid Restructuring","url":"https://stock-news.laohu8.com/highlight/detail?id=2517546695","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517546695?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:39","pubTimestamp":1741383540,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics said it would lay off half of its workforce in a restructuring that came as the company narrowed its loss and logged higher revenue in the fourth quarter.The immunotherapy company said Friday that it will retain about 35 employees, whose roles are essential to operations.The company had 225 employees as of Dec. 31, 2023, according to the latest headcount available in filings with the Securities and Exchange Commission. However, other workforce reductions have taken place since then, including in January 2024, when the company's workforce was cut by a quarter.The development of Ebvallo was halted earlier this year after the Food and Drug Administration placed the drug on a clinical hold. Nguyen said that the company will continue to work toward a path to release the clinical hold and resubmit an application for the treatment.At the same time, the company will pause development of its allogeneic CAR-T cell programs and discontinue all CAR-T operations, he said.For t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2517616134","title":"Atara Biotherapeutics: Q4 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2517616134","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517616134?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:16","pubTimestamp":1741382208,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif.  — THOUSAND OAKS, Calif.  — Atara Biotherapeutics Inc.  on Friday reported a loss of $12.7 million in its fourth quarter.The Thousand Oaks, California-based company said it had a loss of $1.19 per share.The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $3.82 per share.The drug developer posted revenue of $32.8 million in the period.For the year, the company reported that its loss narrowed to $85.4 million, or $11.41 per share. Revenue was reported as $128.9 million.Atara Biotherapeutics shares have dropped 48% since the beginning of the year. In the final minutes of trading on Friday, shares hit $6.88, a drop of 60% in the last 12 months.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atara-biotherapeutics-q4-earnings-snapshot-211648374.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ATRA"],"gpt_icon":0},{"id":"2517946518","title":"Atara Biotherapeutics reports Q4 EPS ($1.19) vs. ($14.00) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2517946518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517946518?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:06","pubTimestamp":1741381591,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $32.75M vs. $4.25M last year. “We will further narrow our focus on the future financial value of EBVALLO for the benefit of all ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reports-q4-eps-1-19-vs-14-00-last-year?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/atara-biotherapeutics-reports-q4-eps-1-19-vs-14-00-last-year?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ATRA"],"gpt_icon":0},{"id":"2517246372","title":"Atara Biotherapeutics Q4 2024 GAAP EPS $(1.19) Beats $(3.58) Estimate, Sales $32.753 Miss $19.148M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2517246372","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517246372?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:03","pubTimestamp":1741381425,"startTime":"0","endTime":"0","summary":"Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(1.19) per share which beat the analyst consensus estimate of $(3.58) by 66.76 percent. This is a 91.5 percent increase over losses of $(14.00) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44204443/atara-biotherapeutics-q4-2024-gaap-eps-1-19-beats-3-58-estimate-sales-32-753-miss-19-148m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Atara Biotherapeutics Q4 2024 GAAP EPS $(1.19) Beats $(3.58) Estimate, Sales $32.753 Miss $19.148M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATRA"],"gpt_icon":0},{"id":"2517463755","title":"Atara Biotherapeutics Inc: Strategic Review by Financial Advisor Ongoing","url":"https://stock-news.laohu8.com/highlight/detail?id=2517463755","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517463755?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:01","pubTimestamp":1741381260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nPLX7D560D:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2517463731","title":"Atara Biotherapeutics Inc: Implemented a Workforce Reduction of Approximately 50% to Preserve Resources","url":"https://stock-news.laohu8.com/highlight/detail?id=2517463731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517463731?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:01","pubTimestamp":1741381260,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nPLX7D560D:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ATRA","BK4139"],"gpt_icon":0},{"id":"2517461615","title":"Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2517461615","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517461615?lang=en_us&edition=full_marsco","pubTime":"2025-03-08 05:01","pubTimestamp":1741381260,"startTime":"0","endTime":"0","summary":"Atara is working closely with its partners and the FDA to lift clinical hold and support EBVALLO BLA resubmission in the U.S.Atara remains focused on delivering on the future financial value of EBVALLO and has paused ATA3219 and ATA3431 CAR-T programs and implemented a workforce reduction of approximately 50% to preserve resources. \"We will further narrow our focus on the future financial value of EBVALLO for the benefit of all stakeholders. Atara continues to productively engage with our partner Pierre Fabre Laboratories and the FDA to help the third-party manufacturer adequately address the GMP compliance issues as we continue to work toward an expeditious path to release the clinical hold and resubmit the EBVALLO BLA,\" said Cokey Nguyen, President and Chief Executive Officer of Atara. \"With the focus on future EBVALLO value paramount, the Company has made the difficult decision to pause development of its allogeneic CAR-T cell programs and to discontinue all CAR-T operations includi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/atara-biotherapeutics-announces-fourth-quarter-210100019.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0390134368.USD","LU2065732104.USD","BK4588","PRGS","BK4121","ATRA","BK4585","CRL","BK4530","BK4097","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.atarabio.com","stockEarnings":[{"period":"1week","weight":-0.0699},{"period":"1month","weight":-0.1899},{"period":"3month","weight":-0.6618},{"period":"6month","weight":-0.2815},{"period":"1year","weight":-0.7042},{"period":"ytd","weight":-0.58}],"compareEarnings":[{"period":"1week","weight":-0.115},{"period":"1month","weight":-0.1379},{"period":"3month","weight":-0.1578},{"period":"6month","weight":-0.1383},{"period":"1year","weight":-0.0429},{"period":"ytd","weight":-0.1529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Atara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.363636,"avgChangeRate":0.079335},{"month":2,"riseRate":0.272727,"avgChangeRate":-0.062727},{"month":3,"riseRate":0.454545,"avgChangeRate":0.043828},{"month":4,"riseRate":0.090909,"avgChangeRate":-0.076074},{"month":5,"riseRate":0.4,"avgChangeRate":-0.075569},{"month":6,"riseRate":0.7,"avgChangeRate":0.075872},{"month":7,"riseRate":0.6,"avgChangeRate":-0.046068},{"month":8,"riseRate":0.5,"avgChangeRate":-0.037443},{"month":9,"riseRate":0.7,"avgChangeRate":0.015932},{"month":10,"riseRate":0.2,"avgChangeRate":-0.106288},{"month":11,"riseRate":0.818182,"avgChangeRate":0.252155},{"month":12,"riseRate":0.272727,"avgChangeRate":-0.092634}],"exchange":"NASDAQ","name":"Atara Biotherapeutics","nameEN":"Atara Biotherapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.2","shortVersion":"4.32.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Atara Biotherapeutics(ATRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Atara Biotherapeutics,ATRA,Atara Biotherapeutics股票,Atara Biotherapeutics股票老虎,Atara Biotherapeutics股票老虎国际,Atara Biotherapeutics行情,Atara Biotherapeutics股票行情,Atara Biotherapeutics股价,Atara Biotherapeutics股市,Atara Biotherapeutics股票价格,Atara Biotherapeutics股票交易,Atara Biotherapeutics股票购买,Atara Biotherapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Atara Biotherapeutics(ATRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Atara Biotherapeutics(ATRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction